Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

ESRRA facilitates hepatocellular carcinoma progression through transcriptional activation of PHF5A and serves as a potential therapeutic target of rosuvastatin.

Created on 11 Nov 2026

Authors

Xiang Cai, Zhiping Wan, Shuying Huang, Yutian Chong, Yusheng Jie, Xiangyong Li, Jiao Gong

Published in

Cellular signalling. Pages 113001. Nov 10, 2026. Epub Nov 10, 2026.

Abstract

The estrogen-related receptor alpha (ESRRA), a member of the estrogen receptor-related receptor family, has been implicated in tumor progression across multiple cancers. However, its function and molecular mechanisms in hepatocellular carcinoma (HCC) remain incompletely understood. Moreover, statins improve the prognosis of HCC patients in clinical trials, while the underlying mechanisms remain unclear.
ESRRA expression was analyzed in public databases, clinical HCC tissues and cell lines. The effects of ESRRA and rosuvastatin on HCC cell proliferation and migration were examined in vitro (CCK-8, colony formation, EdU proliferation, wound-healing, transwell assays, and epithelial-mesenchymal transition (EMT) marker analysis) and in vivo (subcutaneous xenograft, lung metastasis, and orthotopic liver tumor models). RNA sequencing, dual-luciferase reporter assays, ChIP-qPCR, and co-IP identified ESRRA's downstream targets and pathways.
ESRRA was significantly upregulated in clinical HCC specimens and cell lines. Functional assays showed that ESRRA promoted HCC cell proliferation and migration in vitro and in vivo. Mechanistically, ESRRA interacted with coactivator PGC1α and transcriptionally upregulated PHD finger protein 5 A (PHF5A), which was associated with enhanced PI3K/AKT signaling and downstream genes related to cell cycle progression and apoptosis. Furthermore, rosuvastatin exerted anti-tumor activity in HCC and potentiated lenvatinib-induced HCC cell suppression by downregulating ESRRA and inhibiting its transcriptional function via reducing intracellular cholesterol.
ESRRA/PGC1α promotes HCC progression via an ESRRA-PHF5A axis that is required for PI3K/AKT pathway activity and mediates rosuvastatin's anti-tumor effect. Targeting ESRRA-PHF5A may be a therapeutic strategy for HCC.

PMID:
43008960
Bibliographic data and abstract were imported from PubMed on 11 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement